ASA- and Clopidogrel-Responsiveness in Patients With Peripheral Arterial Occlusive Disease and Interventional Procedures
This study has suspended participant recruitment.
Sponsor:
Johann Wolfgang Goethe University Hospitals
Information provided by:
Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier:
NCT00593762
First received: January 3, 2008
Last updated: March 15, 2010
Last verified: January 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to determine the response to aspirin (ASA) and Clopidogrel in patients with peripheral arterial occlusive disease (PAOD) requiring interventional procedures and to investigate if patients with "resistance" to ASA or Clopidogrel have an unfavourable outcome during long-term follow-up
| Condition |
|---|
|
Peripheral Arterial Occlusive Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Investigation of Laboratory Resistance to Aspirin and Clopidogrel and Its Clinical Relevance in Patients With Peripheral Arterial Occlusive Disease Requiring Interventional Procedures |
Resource links provided by NLM:
Further study details as provided by Johann Wolfgang Goethe University Hospitals:
Primary Outcome Measures:
- Need for peripheral arterial revascularisation [ Time Frame: 1, 6, 12 and 24 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Cardiovascular events (death, myocardial infarction, stroke, ACS, PCI) [ Time Frame: 1, 6, 12 and 24 months ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Whole blood, serum
| Estimated Enrollment: | 200 |
| Study Start Date: | May 2005 |
| Estimated Study Completion Date: | December 2009 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
patients with peripheral arterial occlusive disease (PAOD) requiring a catheter interventional procedure
Criteria
Inclusion Criteria:
- PAOD patients
- Age 18-85 years
- Need for a catheter interventional procedure
- Antithrombotic therapy with aspirin or clopidogrel
Exclusion Criteria:
- Comedication additionally compromising platelet function
- Known bleeding disorder
- Life expectancy < 6 months
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00593762
Locations
| Germany | |
| Division of Vascular Medicine, Department of Internal Medicine, J.W.Goethe University Hospital | |
| Frankfurt/Main, Hessen, Germany, D-60590 | |
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospitals
Investigators
| Principal Investigator: | Birgit Linnemann, MD | Division of Vascular Medicine, Department of Internal Medicine, J.W. Goethe University Hospital Frankfurt |
More Information
No publications provided
| Responsible Party: | PD Dr. E. Lindhoff-Last, Division of Vascular Medicine, Department of Internal Medicine, J.W.Goethe University Hospital Frankfurt |
| ClinicalTrials.gov Identifier: | NCT00593762 History of Changes |
| Other Study ID Numbers: | E 19/05 |
| Study First Received: | January 3, 2008 |
| Last Updated: | March 15, 2010 |
| Health Authority: | Germany: Ethics Commission |
Keywords provided by Johann Wolfgang Goethe University Hospitals:
|
Peripheral arterial occlusive disease Aspirin Clopidogrel |
Resistance Catheter interventional procedure ASA and clopidogrel resistance |
Additional relevant MeSH terms:
|
Arterial Occlusive Diseases Peripheral Arterial Disease Vascular Diseases Cardiovascular Diseases Atherosclerosis Arteriosclerosis Peripheral Vascular Diseases Clopidogrel Platelet Aggregation Inhibitors Hematologic Agents |
Therapeutic Uses Pharmacologic Actions Purinergic P2Y Receptor Antagonists Purinergic P2 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 16, 2013